Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375310 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
A Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00375310 is a Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 27 participants.
The verdict
NCT00375310, a Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of the combined treatment of Sorafenib (BAY 43-9006) with Gemcitabine and radiotherapy in patients with localized unresectable pancreatic cancer.
Interventions
- PROCEDURE Radiotherapy
- DRUG Gemcitabine, Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-09 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00375310
The ClinicalTrials.gov registry entry for NCT00375310 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiotherapy is the first listed.
NCT00375310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00375310 about?
NCT00375310 is a clinical study titled "Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer". The purpose of this study is to evaluate the safety and tolerability of the combined treatment of Sorafenib (BAY 43-9006) with Gemcitabine and radiotherapy in patients with localized unresectable pancreatic cancer.
What is the current status of trial NCT00375310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2006-09. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00375310?
The interventions under investigation include: Radiotherapy (PROCEDURE), Gemcitabine, Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00375310?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.